C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, announced that it has entered into an exclusive license and collaboration agreement with Merck, known as MSD outside of the United States and Canada, to develop degrader-antibody conjugates (DACs), an emerging modality designed to selectively target and neutralize disease-causing proteins in cancer cells.